International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 419-420 , May 2010

Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?

  • Jason A. Roberts

      Affiliations

    • Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    • Department of Intensive Care, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia
    • Corresponding Author InformationCorresponding author. Present address: Burns, Trauma and Critical Care Research Centre, Level 3 Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield Street, Brisbane, Queensland 4029, Australia.
  • Jeffrey Lipman

      Affiliations

    • Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    • Department of Intensive Care, Royal Brisbane and Women's Hospital, Brisbane, Australia

References 

  1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329
  2. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668
  3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10
  4. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002;19:349–353
  5. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–2751
  6. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care. 2006;10:R111
  7. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596
  8. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38:284–288
  9. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851
  10. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268–2282
  11. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590–1597
  12. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–150
  13. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30:11–18
  14. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic–pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother. 2006;58:987–993

PII: S0924-8579(10)00067-1

doi: 10.1016/j.ijantimicag.2010.01.022

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 419-420 , May 2010

Article Tools